Abstract：
Oral Montelukast is recommended as maintenance therapy for persistent asthma, but there is controversy regarding its effectiveness in controlling asthma attacks. The present study was conducted to investigate the clinical efficacy of oral Montelukast for asthma attacks in children. This study was conducted as a double-blind placebo-controlled clinical trial on 80 children aged 1-14 years with asthma who were admitted to the emergency department of Bahrami Children\'s Hospital (Tehran, Iran) during one year. Patients were randomly divided into case and control groups. In addition to the standard asthma attack treatment, Montelukast was prescribed in the case group and placebo in the control group for one week. Patients were evaluated in terms of asthma attack severity score and oxygen saturation percentage (SpO2) in room air as primary outcomes 1, 4, 8, 24 and 48 hours after admission. In the first 48 hours, there was no significant difference in the score of asthma attack severity and SpO2 between the case and control groups. There was no significant difference between the groups in terms of length of hospitalization or number of admissions to the intensive care unit. None of the patients were re-hospitalized after discharge. The results of this study showed that the use of Montelukast along with the standard treatment of asthma attacks in children has no added benefit.
摘要：
口服孟鲁司特被推荐作为持续性哮喘的维持治疗，但关于其控制哮喘发作的有效性存在争议。本研究旨在探讨口服孟鲁司特治疗儿童哮喘发作的临床疗效。这项研究是作为一项双盲安慰剂对照临床试验，对80名1-14岁哮喘儿童进行的，这些儿童被送往Bahrami儿童医院急诊科（德黑兰，伊朗）在一年内。将患者随机分为病例组和对照组。除了标准的哮喘发作治疗，在病例组中使用孟鲁司特，在对照组中使用安慰剂，持续一周。根据哮喘发作严重程度评分和室内空气中氧饱和度百分比（SpO2）评估患者，作为入院后1、4、8、24和48小时的主要结果。在最初的48小时内，病例组和对照组的哮喘发作严重程度和SpO2评分无显著差异.两组在住院时间或重症监护病房入院人数方面没有显着差异。出院后没有患者再次住院。这项研究的结果表明，使用孟鲁司特以及儿童哮喘发作的标准治疗没有额外的益处。
